Cargando…
Reply to: Do interleukin 17 inhibitors increase risk of respiratory tract infections?
Autores principales: | Blauvelt, Andrew, Ehst, Benjamin D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328562/ https://www.ncbi.nlm.nih.gov/pubmed/32622137 http://dx.doi.org/10.1016/j.jaad.2020.06.1000 |
Ejemplares similares
-
Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
por: Wan, Marilyn T., et al.
Publicado: (2020) -
Reply: Potential role of Janus kinase inhibitors in COVID-19
por: Napolitano, Maddalena, et al.
Publicado: (2020) -
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19
por: Peterson, Danielle, et al.
Publicado: (2020) -
Reply to research letter
por: Rivera-Oyola, Ryan, et al.
Publicado: (2020) -
Reply to: “Reply: A dermatologic manifestation of COVID-19: Transient livedo reticularis”
por: Manalo, Iviensan F., et al.
Publicado: (2020)